NeuroVive Initiates Collaboration With Leading US TBI Research Organization
LUND, Sweden, May 2, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced a partnership with TRACK-TBI, a network of US-based world-leading TBI clinicians and researchers. The purpose of the network that NeuroVive now will be a part of intends to ...
Amendment: Resolutions From Annual General Meeting in NeuroVive Pharmaceutical AB (publ)
LUND, Sweden, 27 April 2018 /PRNewswire/ --NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF)("NeuroVive") today on 27 April 2018 held its Annual General Meeting (AGM). A summary of the resolutions follows. All resolutions were passed with the required majority. Approval of prof...
Resolutions From Annual General Meeting in NeuroVive Pharmaceutical AB (publ)
LUND, Sweden, 27 April, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) ("NeuroVive") today on 27 April 2018 held its Annual General Meeting (AGM). A summary of the resolutions follows. All resolutions were passed with the required majority. Approval of p...
NeuroVive Presents NVP025 Mitochondrial Myopathy Project Progress at Mitochondrial Medicine Conference
LUND, Sweden, April 20, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that its mitochondrial myopathy project, NVP025, has been selected for an oral presentation at the prestigious Mitochondrial Medicine 2018 conference held on 9-11 May in...
NeuroVive's Board Members, Senior Executives and Employees Will Subscribe Units in the Ongoing Rights Issue
STOCKHOLM, April 20, 2018 /PRNewswire/ -- In the current rights issue in NeuroVive, the Board, Senior Executives and employees have undertaken to subscribe for at least 191,200 units equivalent to MSEK 1.5. The subscription period in the current rights issue in NeuroVive is ongoing untilApril 2...
NeuroVive's KL1333 Receives FDA Orphan Drug Designation for Treatment of Mitochondrial Diseases
LUND, Sweden, April 18, 2018 /PRNewswire/ --NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF), the mitochondrial medicine company, today announced that it has been granted Orphan Drug Designation by the United States FDA Office of Orphan Products Development for its project KL133...
NeuroVive's Partner Yungjin Pharm Completes KL1333 Phase I Study Recruitment
LUND, Sweden, April 17, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today announced that the last visit of the last healthy volunteer in the clinical phase I single ascending dose ...
NeuroVive Pharmaceutical AB Year End Report January - December 2017
STOCKHOLM, Feb. 20, 2018 /PRNewswire/ -- Business operations Significant events October-December 2017 * NeuroVive received a positive opinion from the EMA's Committee for Orphan Medicinal Products (COMP) regarding orphan drug designation for KL1333. * Greg Batcheller, the Chairman of NeuroVi...
Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)
LUND, Sweden, Feb. 15, 2018 /PRNewswire/ -- The shareholders of NeuroVive Pharmaceutical AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting, held at2 pm on Thursday 22 March 2018 at Medicon Village, Scheelevagen 2, in Lund, Sweden. Entitlement to participate and no...
NeuroVive Decides on a Rights Issue for Continued Drug Development
LUND, Sweden, Feb. 15, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (publ) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces that the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "the Company") on15 February 2018 resolved, subject to approval by the Extraordinary Gen...
NeuroVive Reports Breakthrough in Mitochondrial Myopathy Project
LUND, Sweden, Jan. 29, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced a breakthrough in the company's project NVP025 for developing treatment of mitochondrial myopathy. In an experimental study carried out in collaboration with researchers at...
NeuroVive to Present at the 10th Annual Biotech Showcase Conference
LUND, Sweden, Jan. 3, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announced that the company is scheduled to present the 10th Annual Biotech Showcase Conference, held8-10 January 2018 in San Francisco, USA. The presentation will highlight the com...
NeuroVive's KL1333 Program Granted Orphan Drug Designation by the European Commission
LUND, Sweden, Dec. 13, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF), announced today that the European Commission has granted orphan drug designation (ODD) for the company's KL1333 program for oral treatment of the genetic mitochondrial disease Mitochondr...
NeuroVive Reports Promising Progress in its Clinical Project for Genetic Mitochondrial Diseases, KL1333
LUND, Sweden, Dec. 11, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm today announced that the phase I clinical study in Korea within the companies' joint project KL1333, an investigational treatment for genetic mitochondrial disorders, inc...
Amended Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ)
LUND, Sweden, Nov. 30, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced an increase of the number of shares and votes in NeuroVive of 1,760,000 as a result of a directed share issue in NeuroVive Pharmaceuti...
NeuroVive's Genetic Mitochondrial Disease Program NVP015 Reaches Significant Milestone
LUND, Sweden, Nov. 30, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that molecules in its NVP015 program have demonstrated positive effects in experimental models of genetic mitochondrial disease and th...
NeuroVive Pharmaceutical AB Interim Report January - September 2017
STOCKHOLM, Nov. 21, 2017 /PRNewswire/ -- Business operations Significant events July-September 2017 * NeuroVive received positive feedback from the European Medicines Agency (EMA) regarding the NeuroSTAT development plan. * NeuroVive signed a private placement agreement with Esousa Holdings...
NeuroVive Presents TBI Clinical Study Results at Nordic Neurotrauma Conference
LUND, Sweden, Nov. 15, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company will present data from its clinical phase IIa study on traumatic brain injury (TBI), Copenhagen Head Injury Ciclosporin Study (CHIC), at the Nordic Neurot...
NeuroVive Board Chair Resigns, New Chair Elected
LUND, Sweden, Nov. 7, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces thatGregory Batcheller resigned as Chair of the NeuroVive Pharmaceutical AB Board effective midnightNovember 6, 2017. He had served as the Executive Chair of NeuroVive for the p...
NeuroVive Conducts a Directed New Share Issue of SEK 5.3 Million
LUND, Sweden, Nov. 3, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), a leading company in mitochondrial medicine, announced today that the company is conducting a directed new issue of shares, which is expected to add close toSEK 5.3 million to NeuroVive...
